[A clinical study on cefpodoxime proxetil dry syrup in pediatric infections].
Clinical studies on cefpodoxime proxetil (CS-807, CPDX-PR) dry syrup were carried out in the field of pediatrics, and the results are summarized as follows. 1. Eleven year-old male and 12 year-old female were administered orally at a dose level of 5.6 and 6.0 mg/kg, respectively, after or before meal. Cmax and T1/2 were 5.0 micrograms/ml and 2.13 hours, respectively, for the male and 4.04 micrograms/ml and 1.63 hours, respectively, for the female. 2. Good clinical responses were obtained in 21 of 22 child patients with bacterial pharyngitis, tonsillitis, scarlet fever and urinary tract infections. One child with Mycoplasma pneumonia did not respond. As to bacteriological effects, eradication of pathogens was observed in 8 out of 11 strains, showing an eradication rate of 72.7%. 3. As to side effect, 1 case of loose stool was observed, but there was no need of discontinuing the drug treatment.
Wagatsuma
Y
Y
Department of Pediatrics, Sapporo City General Hospital.
Takase
A
A
Fukushima
N
N
Ishikawa
A
A
Takahashi
S
S
D000284:Administration, Oral; D000293:Adolescent; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism / Q000382:microbiology; D015296:Ceftizoxime / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000627:therapeutic use; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D010612:Pharyngitis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D014069:Tonsillitis / Q000188:drug therapy / Q000378:metabolism / Q000382:microbiology; D000097627:Cefpodoxime Proxetil
D015296:Ceftizoxime; D000097627:Cefpodoxime Proxetil